Trial intelligence / Profile preview

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID

NCT06821087Phase 2

Key facts

Status: Completed
Start: Jun 2025
Primary completion: Jun 2026
Countries: 1
Sponsor: University of Texas at Austin
Modality: Small Molecules

Drugs: ketamine
Conditions: post-COVID-19 condition (PCC)

Overview

Phase 2, open-label, single-arm trial of ketamine in post-COVID-19 condition (PCC), sponsored by University of Texas at Austin. Primary endpoints: PROMIS SF v1.0 - Fatigue 8a at 8 weeks and PROMIS SF v2.0 Cognitive Function 4a at 8 weeks. Started Jun 2025; status: completed.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Ketamine Therapy
Four IM ketamine injections over a two-week period.

Who it enrols

Adults aged 18-65 with Long COVID and persistent fatigue or neurocognitive dysfunction, excluding those with severe psychiatric disorders, unstable cardiovascular disease, or recent use of benzodiazepines or naltrexone.

Endpoints

Primary

PROMIS SF v1.0 - Fatigue 8a8 weeks
PROMIS SF v2.0 Cognitive Function 4a8 weeks

Secondary

PROMIS Global 10 v1.28 weeks
NASA Task Load Index8 weeks
Patient Health Questionnaire-98 weeks
Number of participants with treatment-related adverse events8 weeks
BrainCheck Cognitive Battery8 weeks
Generalized Anxiety Disorder-78 weeks
Depression in Medically Ill 10 Scale8 weeks
Long COVID Review of Systems8 weeks

Beyond the preview

Go deeper on NCT06821087.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06821087.